SETDB1 mediated FosB expression increases the cell proliferation rate during anticancer drug therapy
0
조회
0
다운로드
6
인용
0
참고문헌
키워드
초록
The efficacy of anticancer drugs depends on a variety of signaling pathways, which can be positively or negatively regulated. In this study, we show that SETDB1 HMTase is down-regulated at the transcriptional level by several anticancer drugs, due to its inherent instability. Using RNA sequence analysis, we identified FosB as being regulated by SETDB1 during anticancer drug therapy. FosB expression was increased by treatment with doxorubicin, taxol and siSETDB1. Moreover, FosB was associated with an increased rate of proliferation. Combinatory transfection of siFosB and siSETDB1 was slightly increased compared to transfection of siFosB. Furthermore, FosB was regulated by multiple kinase pathways. ChIP analysis showed that SETDB1 and H3K9me3 interact with a specific region of the FosB promoter. These results suggest that SETDB1- mediated FosB expression is a common molecular phenomenon, and might be a novel pathway responsible for the increase in cell proliferation that frequently occurs during anticancer drug therapy.
Abstract
The efficacy of anticancer drugs depends on a variety of signaling pathways, which can be positively or negatively regulated. In this study, we show that SETDB1 HMTase is down-regulated at the transcriptional level by several anticancer drugs, due to its inherent instability. Using RNA sequence analysis, we identified FosB as being regulated by SETDB1 during anticancer drug therapy. FosB expression was increased by treatment with doxorubicin, taxol and siSETDB1. Moreover, FosB was associated with an increased rate of proliferation. Combinatory transfection of siFosB and siSETDB1 was slightly increased compared to transfection of siFosB. Furthermore, FosB was regulated by multiple kinase pathways. ChIP analysis showed that SETDB1 and H3K9me3 interact with a specific region of the FosB promoter. These results suggest that SETDB1- mediated FosB expression is a common molecular phenomenon, and might be a novel pathway responsible for the increase in cell proliferation that frequently occurs during anticancer drug therapy.
참고문헌 (35)
- Giussani P, "Sphingolipids : key regulators of apoptosis, pivotal players in cancer drug resistance", Int J Mol Sci, 15, pp.4356~4392 (2014)
- Yang W, "AMP-activated protein kinase alpha2, E2F1 transcription factor mediate doxorubicin-induced cytotoxicity by forming a positive signal loop in mouse embryonic fibroblasts, non-carcinoma cells", J Biol Chem, 289, pp.4839~4852 (2014)
- Korbakis D, "Quantitative expression analysis of the apoptosis-related genes BCL2, BAX, BCL2L12 in gastric adenocarcinoma cells following treatment with the anticancer drugs cisplatin, etoposide, taxol", Tumour Biol, 33, pp.865~875 (2012)
- Choi YH, "Taxol-induced growth arrest, apoptosis is associated with the upregulation of the Cdk inhibitor, p21WAF1", CIP1, in human breast cancer cells, 2012, pp.28, 2163~2169
- Liu Z, "The Upregulation of PI3K", Akt, MAP Kinase Pathways is Associated with Resistance of Microtubule-Targeting Drugs in Prostate Cancer, 2015, pp.116, 1341~1349
- Jung KA, "The c-MET", PI3K signaling is associated with cancer resistance to doxorubicin, photodynamic therapy by elevating BCRP, Mol Pharmacol, pp.2015, 87[DOI]
- Guetg C, "Formation of nuclear heterochromatin:the nucleolar point of view", Epigenetics, 7, pp.811~814 (2012)
- Meier K, "Chromatin regulation: how complex does it get?", Epigenetics, 9, pp.1485~1495 (2014)
- Kamiunten T, "Coordinated expression of H3K9 histone methyltransferases during tooth development in mice", Histochem Cell Biol, 143, pp.259~266 (2015)
- Zhang Y, "FOXA1 antagonizes EZH2-mediated CDKN2A repression in carcinogenesis", Biochem Biophys Res Commun, 453, pp.172~178 (2014)
- Ayrapetov MK, "DNA double-strand breaks promote methylation of histone H3 on lysine 9, transient formation of repressive chromatin", Proc Natl Acad Sci U S A, 111, pp.9169~9174 (2014)
- Zhang J, "Ezh2 maintains retinal progenitor proliferation, transcriptional integrity, and the timing of late differentiation", Dev Biol, 403, pp.128~138 (2015)
- 송영준, "Setdb1 Is Required for Myogenic Differentiation of C2C12 Myoblast Cells via Maintenance of MyoD Expression", Molecules and Cells, 38(4), pp.362~372 (2015), 한국분자세포생물학회
- Thompson PJ, "hnRNP K coordinates transcriptional silencing by SETDB1 in embryonic stem cells", PLoS Genet, 11, pp.e1004933~ (2015)
- Schultz DC, "SETDB1 : a novel KAP-1-associated histone H3, lysine 9-specific methyltransferase that contributes to HP1-mediated silencing of euchromatic genes by KRAB zinc-finger proteins", Genes Dev, 16, pp.919~932 (2002)
- Wu PC, "H3K9 histone methyltransferase, KMT1E", SETDB1, cooperates with the SMAD2, Cancer Res, pp.2014, 74[DOI]
- Lee JK, "DZNep, inhibitor of S-adenosylhomocysteine hydrolase, down-regulates expression of SETDB1 H3K9me3 HMTase in human lung cancer cells", Biochem Biophys Res Commun, 438, pp.647~652 (2013)
- Noh HJ, "p53 down-regulates SETDB1 gene expression during paclitaxel induced-cell death", Biochem Biophys Res Commun, 446, pp.43~48 (2014)
- Ceol CJ, "The histone methyltransferase SETDB1 is recurrently amplified in melanoma, accelerates its onset", Nature, 471, pp.513~517 (2011)
- Rodriguez-Paredes M, "Gene amplification of the histone methyltransferase SETDB1 contributes to human lung tumorigenesis", Oncogene, 33, pp.2807~2813 (2014)
- Wakabayashi Y, "Histone 3lysine 9(H3K9)methyltransferase recruitment to the interleukin-2(IL-2)promoter is a mechanism of suppression of IL-2 transcription by the transforming growth factor-beta-Smad pathway", J Biol Chem, 286, pp.35456~35465 (2011)
- Martin FJ, "KMT1E-mediated chromatin modifications at the FcgammaRIIb promoter regulate thymocyte development", Genes Immun, 16, pp.162~169 (2015)
- Ramachandran A, "FosB regulates stretch-induced expression of extracellular matrix proteins in smooth muscle", Am J Pathol, 179, pp.2977~2989 (2011)
- Ratajczak-Wrona W, "PI3K-Akt", PKB signaling pathway in neutrophils, mononuclear cells exposed to N-nitrosodimethylamine, 2014, pp.11, 231~237
- Win-Shwe TT, "Activation of transcription factors in a mouse lung following exposure to environmental chemical, biological agents", J Toxicol Sci, 40, pp.559~568 (2015)
- Hong S, "AP-1 protein induction during monopoiesis favors C", EBP:AP-1 heterodimers over C, J Leukoc Biol, pp.2011, 90[DOI]
- Lazenka MF, "Delta FosB, AP-1-mediated transcription modulate cannabinoid CB(1)receptor signaling, desensitization in striatal, limbic brain regions", Biochem Pharmacol, 91, pp.380~389 (2014)
- Ruffle JK, "Molecular neurobiology of addiction:what's all the (Delta)FosB about?", Am J Drug Alcohol Abuse, 40, pp.428~437 (2014)
- Vialou V, "Differential induction of FosB isoforms throughout the brain by fluoxetine, chronic stress", Neuropharmacology, 99, pp.28~37 (2015)
- Bunjobpol W, "Suppression of acetylpolyamine oxidase by selected AP-1 members regulates DNp73abundance: mechanistic insights for overcoming DNp73-mediated resistance to chemotherapeutic drugs", Cell Death Differ, 21, pp.1240~1249 (2014)
- Spyropoulou A, "Role of histone lysine methyltransferases SUV39H1, SETDB1 in gliomagenesis: modulation of cell proliferation, migration, and colony formation", Neuromolecular Med, 16, pp.70~82 (2014)
- Pallante P, "CBX7 modulates the expression of genes critical for cancer progression", PLoS One, 9, pp.e98295~ (2014)
- Scott CL, "Role of the chromobox protein CBX7 in lymphomagenesis", Proc Nat Acad Sci U S A, 104, pp.5389~5394 (2007)
- 임창임, "Overexpression of tumor necrosis factor receptor-associated protein 1 (TRAP1), leads to mitochondrial aberrations in mouse fibroblast NIH", 3T3 cells, 2014, pp.47(5), 280~285[DOI]
- Shang Y, "Cofactor dynamics, sufficiency in estrogen receptor-regulated transcription", Cell, 103, pp.843~852 (2000)